IRWD Share Price Performance
US$0
-1.47 (-100.00%)
Price US$0
Fair ValueUS$4.85
Share Pricen/a
Ironwood Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 29 Fair Values set on narratives written by author
IRWD Community Narratives
AN
Fair Value US$4.85 33.4% undervalued intrinsic discount
Worsening Revenue Outlook Will Limit Upside Despite Improving Profit Margins
1users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
Fair Value US$10 67.7% undervalued intrinsic discount
Rising GI Trends And Aging Populations Will Expand Therapy Use
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$0.7 361.4% overvalued intrinsic discount
Regulatory Delays And Pricing Headwinds Will Impede Performance But Stabilize
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Rising GI Trends And Aging Populations Will Expand Therapy Use
Key Takeaways New product launches in rare diseases and sustained growth of core GI therapies support expanding revenues, improved margins, and robust cash flow generation. Strong cost discipline and commercial expertise position the company for future pipeline development and diversification, reducing dependence on individual products.Read more
42
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$10
67.7% undervalued intrinsic discount
Fair Value
Revenue
19.92% p.a.
Profit Margin
48.05%
Future PE
8.77x
Price in 2029
US$12.91
Worsening Revenue Outlook Will Limit Upside Despite Improving Profit Margins
Key Takeaways Strategic focus on apraglutide could expand market presence and drive significant revenue growth post-launch, alongside LINZESS providing steady cash flow. Debt reduction and cost-saving measures from restructuring aim to enhance financial stability and improve long-term net margins.Read more
239
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$4.85
33.4% undervalued intrinsic discount
Fair Value
Revenue
11.87% p.a.
Profit Margin
48.12%
Future PE
4.48x
Price in 2029
US$6.18
Regulatory Delays And Pricing Headwinds Will Impede Performance But Stabilize
Key Takeaways Heavy reliance on new drug approvals and reimbursement stability exposes future revenues and margins to regulatory, market, and policy uncertainties. Growth opportunities from pipeline diversification are limited by small target markets and potential slow uptake, posing risk to sustained earnings expansion.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$0.7
361.4% overvalued intrinsic discount
Fair Value
Profit Margin
10.54%
Future PE
9.35x
Price in 2028
US$0.97
Trending Discussion
Recently Updated Narratives
AN
IRWD: Reinforced 2026 Guidance And Legal Resolution Will Support Future Cash Flows
Fair Value: US$10 67.7% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IRWD: Medicare Pricing Clarity And Revenue Outlook Will Shape Balanced Share Prospects
Fair Value: US$4.85 33.4% undervalued intrinsic discount
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Delays And Pricing Headwinds Will Impede Performance But Stabilize
Fair Value: US$0.7 361.4% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ironwood Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 0.15
- 67.88%
- 8.11%
- -223.3%
About IRWD
- Founded
- 1998
- Employees
- 100
- CEO
- WebsiteView website
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
